Spero Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03376529
- Locations
- 🇬🇧
Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT03022175
- Locations
- 🇦🇺
CMAX - A division of IDT Australia, Limited, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath